Vasohibin1, a new mouse cardiomyocyte IRES trans-acting factor that regulates translation during early hypoxia

Abstract

Hypoxia, a major inducer of angiogenesis, triggers major changes of gene expression at the transcriptional level. Furthermore, global protein synthesis is blocked while internal ribosome entry sites (IRES) allow specific mRNAs to be translated. Here we report the transcriptome and translatome signatures of (lymph)angiogenic genes in hypoxic HL-1 mouse cardiomyocytes: most genes are induced at the translatome level, including all IRES-containing mRNAs. Our data reveal activation of (lymph)angiogenic factor mRNA IRESs in early hypoxia. We identify vasohibin1 (VASH1) as an IRES trans-acting factor (ITAF) able to bind RNA and to activate the FGF1 IRES in hypoxia while it tends to inhibit several IRESs in normoxia. VASH1 depletion has also a wide impact on the translatome of (lymph)angiogenesis genes, suggesting that this protein can regulate translation positively or negatively in early hypoxia. Translational control thus appears as a pivotal process to trigger new vessel formation in ischemic heart.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Lentivector plasmid complete maps and sequences are available on Dryad.

The following data sets were generated

Article and author information

Author details

  1. Fransky Hantelys

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Anne-Claire Godet

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Florian David

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Florence Tatin

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Edith Renaud-Gabardos

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Françoise Pujol

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Leila H Diallo

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Isabelle Ader

    Stromalab, Inserm U1031, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Laetitia Ligat

    CRCT, Inserm UMR 1037, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Anthony K Henras

    Centre de Biologie Intégrative, Université Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Yasufumi Sato

    Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku Universtiy, Sendai, Japan
    Competing interests
    The authors declare that no competing interests exist.
  12. Angelo Parini

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Eric Lacazette

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Barbara Garmy-Susini

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Anne-Catherine Prats

    I2MC, Inserm UMR 1048, Toulouse, France
    For correspondence
    anne-catherine.prats@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5282-3776

Funding

Region Midi-Pyrenees

  • Anne-Catherine Prats

AFM-Téléthon

  • Edith Renaud-Gabardos
  • Anne-Catherine Prats

Association pour la Recherche sur le Cancer

  • Anne-Catherine Prats

European Commission (REFBIO VEMT)

  • Anne-Catherine Prats

Fondation Toulouse Cancer-Sante

  • Barbara Garmy-Susini

Agence Nationale de la Recherche (ANR-18-CE11-0020-RIBOCARD)

  • Anne-Catherine Prats

Ligue Contre le Cancer

  • Fransky Hantelys
  • Anne-Claire Godet

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2019, Hantelys et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,668
    views
  • 256
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Fransky Hantelys
  2. Anne-Claire Godet
  3. Florian David
  4. Florence Tatin
  5. Edith Renaud-Gabardos
  6. Françoise Pujol
  7. Leila H Diallo
  8. Isabelle Ader
  9. Laetitia Ligat
  10. Anthony K Henras
  11. Yasufumi Sato
  12. Angelo Parini
  13. Eric Lacazette
  14. Barbara Garmy-Susini
  15. Anne-Catherine Prats
(2019)
Vasohibin1, a new mouse cardiomyocyte IRES trans-acting factor that regulates translation during early hypoxia
eLife 8:e50094.
https://doi.org/10.7554/eLife.50094

Share this article

https://doi.org/10.7554/eLife.50094

Further reading

    1. Cancer Biology
    2. Cell Biology
    Alexandra Urbancokova, Terezie Hornofova ... Pavla Vasicova
    Research Article

    PML, a multifunctional protein, is crucial for forming PML-nuclear bodies involved in stress responses. Under specific conditions, PML associates with nucleolar caps formed after RNA polymerase I (RNAPI) inhibition, leading to PML-nucleolar associations (PNAs). This study investigates PNAs-inducing stimuli by exposing cells to various genotoxic stresses. We found that the most potent inducers of PNAs introduced topological stress and inhibited RNAPI. Doxorubicin, the most effective compound, induced double-strand breaks (DSBs) in the rDNA locus. PNAs co-localized with damaged rDNA, segregating it from active nucleoli. Cleaving the rDNA locus with I-PpoI confirmed rDNA damage as a genuine stimulus for PNAs. Inhibition of ATM, ATR kinases, and RAD51 reduced I-PpoI-induced PNAs, highlighting the importance of ATM/ATR-dependent nucleolar cap formation and homologous recombination (HR) in their triggering. I-PpoI-induced PNAs co-localized with rDNA DSBs positive for RPA32-pS33 but deficient in RAD51, indicating resected DNA unable to complete HR repair. Our findings suggest that PNAs form in response to persistent rDNA damage within the nucleolar cap, highlighting the interplay between PML/PNAs and rDNA alterations due to topological stress, RNAPI inhibition, and rDNA DSBs destined for HR. Cells with persistent PNAs undergo senescence, suggesting PNAs help avoid rDNA instability, with implications for tumorigenesis and aging.

    1. Cell Biology
    Surya Bansi Singh, Shatruhan Singh Rajput ... Deepa Subramanyam
    Research Article

    Aggregation of mutant forms of Huntingtin is the underlying feature of neurodegeneration observed in Huntington's disorder. In addition to neurons, cellular processes in non-neuronal cell types are also shown to be affected. Cells expressing neurodegeneration-associated mutant proteins show altered uptake of ligands, suggestive of impaired endocytosis, in a manner as yet unknown. Using live cell imaging, we show that clathrin-mediated endocytosis (CME) is affected in Drosophila hemocytes and mammalian cells containing Huntingtin aggregates. This is also accompanied by alterations in the organization of the actin cytoskeleton resulting in increased cellular stiffness. Further, we find that Huntingtin aggregates sequester actin and actin-modifying proteins. Overexpression of Hip1 or Arp3 (actin-interacting proteins) could restore CME and cellular stiffness in cells containing Huntingtin aggregates. Neurodegeneration driven by pathogenic Huntingtin was also rescued upon overexpression of either Hip1 or Arp3 in Drosophila. Examination of other pathogenic aggregates revealed that TDP-43 also displayed defective CME, altered actin organization and increased stiffness, similar to pathogenic Huntingtin. Together, our results point to an intimate connection between dysfunctional CME, actin misorganization and increased cellular stiffness caused by alteration in the local intracellular environment by pathogenic aggregates.